Example One ADVANCED COMPOUNDS
FOR NEUROSCIENCE

Mission & Values

We are a Biopharmaceutical company aimed to discover and develop innovative advanced compounds to solve the major neurodegenerative diseases.
Our first focus is on the eyes pathologies for which financial funding is already in place.
We believe that our scientific and innovative approach will open a new field in the pharma-based neurological solutions enabling people to lead longer and healthier lives.
Our mission will require an extraordinary level of interdisciplinary effort that will be ensured by the scientific knowledge within our company and international partner network.

Team

We are people from the fields of medicine, drug & medical development, molecular biology, venture capital.
We may succeed. We may fail but, by working together, with integrity and respect, we will always be doing things the right way, and we just might achieve something that others may not believe possible

Marco Feligioni

Founder and Chief Scientific Officer (CSO)

Marco has a medicinal chemistry degree, PhD in pharmacology and 20+ years of international research in neuroscience (University of Bristol, UK; Karolinska Institutet Stockolm, SE). He published more than 50 publications with h-index >24, 1 Patent released. He is the founder and former CEO of Peptitech

Evarist Granata

Co-Founder

+10 years working experience for leading management consulting company and innovation projects. Business Angel and incubator of several start-ups in ITC, Renewable Energy and social innovation. Business Administration Master degree in Bocconi University. He is Co-Founder and CFO of Peptitech.

Mauro Brunelli

Chief Executive Officer (CEO)

WorkMauro has 10+ years experience in venture capital investments.
Co-founder and former CEO of a Biotech start-up, he also served as business advisor and Board Member for several Life Sciences companies.
15+ years as Head of Corporate Finance and M&A Advisory in Italian and International investment banks.

Francesco Maria Patella

CO-Founder and Legal Affair Board Member

He has a Law degree and MBA at IE Business School with a past working experience in fast growing start-up’s in Italy and UK. Currently involved as private investor in several hi-tech & renewable energy ventures. He is a legal affair board member of Peptitech Ltd.

Massimo Corbo

Scientific Advisor

He has a medicine degree and a specialization in neurology, more than 100 publication in neuroscience, he is Scientific Director of Casa di Cura del Policlinico di Milano in which he directs several clinical trials. From late 2017 he is part of the Scientific Advisory Board of Peptitech Ltd

M. Francesca Cordeiro

Scientific Advisor

She is a clinician scientist specialized in the field of glaucoma and neurodegeneration. She currently heads the “Glaucoma and Retinal Neurodegeneration Research Group” at UCL in London. Author of more than 100 scientific papers, she is part of the Scientific Advisory Board of Peptitech Ltd.

Rita Maccarone

Scientific Collaborator

She is graduated in Biology with a PhD in Neuroscience. She is a neuroscientist and she has focused her research on understanding the physiological bases of the retinal cells also in pathological conditions. She is an expert in studying the retinal diseases using several pathology models. She has spent several years abroad as Post Doc and at the moment she is confirmed researcher at the University of L’Aquila. In her career she has published several papers in international journals. She is a scientific collaborator of Peptitech Srl.

Cristina Geroni

Head preclinical R&D

Cristina has +30 years of experience in preclinical pharmaceutical research and drug development in primary international firms (Farmitalia, Pharmacia, Pfizer) managing successful trials of several early stage drugs. She also founded a start-up in the Life Science.

Mission & Values

We are a Biopharmaceutical firm aimed to develop new advanced biological compounds to solve the major neurodegenerative diseases.
Our first focus is on the eyes pathologies for which financial funding is already in place.
We believe that our scientific and innovative approach will open a new field in the pharma-based neurological solutions enabling people to lead longer and healthier lives.
Our mission will require an extraordinary level of interdisciplinary effort that will be ensured by the scientific knowledge within our company and international partner network.

Team

We are people from the fields of medicine, drug & medical development, molecular biology, venture capital.
We may succeed. We may fail but, by working together, with integrity and respect, we will always be doing things the right way, and we just might achieve something that others may not believe possible

Marco Feligioni

Founder and Chief Scientific Officer (CSO)

Marco has a medicinal chemistry degree, PhD in pharmacology and 20+ years of international research in neuroscience (University of Bristol, UK; Karolinska Institutet Stockolm, SE).
He published more than 50 publications with h-index >24, 1 Patent released.
He is the founder and former CEO of Peptitech

Mauro Brunelli

Chief Executive Officer (CEO)

Mauro has 10+ years experience in venture capital investments.
Co-founder and former CEO of a Biotech start-up, he also served as business advisor and Board Member for several Life Sciences companies.
15+ years as Head of Corporate Finance and M&A Advisory in Italian and International investment banks.

Evarist Granata

Co-Founder

+10 years working experience for leading management consulting company and innovation projects. Business Angel and incubator of several start-ups in ITC, Renewable Energy and social innovation. Business Administration Master degree in Bocconi University. He is Co-Founder and CFO of Peptitech.

Francesco Maria Patella

Co-Founder and Legal Affair Board Member

He has a Law degree and MBA at IE Business School with a past working experience in fast growing start-up’s in Italy and UK. Currently involved as private investor in several hi-tech & renewable energy ventures. He is a legal affair board member of Peptitech Ltd.

Massimo Corbo

Scientific Advisor

He has a medicine degree and a specialization in neurology, more than 100 publication in neuroscience, he is Scientific Director of Casa di Cura del Policlinico di Milano in which he directs several clinical trials. From late 2017 he is part of the Scientific Advisory Board of Peptitech Ltd

M. Francesca Cordeiro

Scientific Advisor

She is a clinician scientist specialized in the field of glaucoma and neurodegeneration. She currently heads the “Glaucoma and Retinal Neurodegeneration Research Group” at UCL in London. Author of more than 100 scientific papers, she is part of the Scientific Advisory Board of Peptitech Ltd.

Rita Maccarone

Scientific Collaborator

She is graduated in Biology with a PhD in Neuroscience. She is a neuroscientist and she has focused her research on understanding the physiological bases of the retinal cells also in pathological conditions. She is an expert in studying the retinal diseases using several pathology models. She has spent several years abroad as Post Doc and at the moment she is confirmed researcher at the University of L’Aquila. In her career she has published several papers in international journals. She is a scientific collaborator of Peptitech Srl.

Cristina Geroni

Head preclinical R&D

Cristina has +30 years of experience in preclinical pharmaceutical research and drug development in primary international firms (Farmitalia, Pharmacia, Pfizer) managing successful trials of several early stage drugs. She also founded a start-up in the Life Science.

Slide Proof of concept PreClinical trial First in human GLAUCONEXT GN-01GRi EPILNEXT EN001 ALZHNEXT AN001

DRUG PIPELINE

GlaucoNext is the first drug project launched by Peptitech for glaucoma disease.
The patented compound ‘GN-01GRi’ is now in pre-clinical phase who expected to finish at the end of year 2019.
Drug development add-on's for neurodegenerative pathologies are expected to start from second half of year 2018.

Scientific partners

Slide